Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™
April 03, 2024 07:05 ET
|
Helius Medical Technologies, Inc.
-- Lovell is an approved supplier to the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) ---- Over 28,000 cases of multiple sclerosis (MS) are reported to the VA annually -- ...
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
March 28, 2024 16:05 ET
|
Helius Medical Technologies, Inc.
-- Company to host call at 4:30pm today -- NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused...
Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
March 15, 2024 07:05 ET
|
Helius Medical Technologies, Inc.
NEWTOWN, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...
Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke
March 12, 2024 08:59 ET
|
Helius Medical Technologies, Inc.
-- Enrollment of at least ten patients at Brooks Rehabilitation will begin this month ---- Study will evaluate the use of Portable Neuromodulation Stimulator (PoNS®) for gait and balance deficits in...
Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference
March 07, 2024 07:00 ET
|
Helius Medical Technologies, Inc.
NEWTOWN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...
Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller
March 04, 2024 07:00 ET
|
Helius Medical Technologies, Inc.
-- Significant step toward reimbursement for the only medical device approved in the U.S. for treatment of gait deficit due to multiple sclerosis (“MS”) -- -- Proceeds from recent stock issuances...
Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients
February 06, 2024 07:00 ET
|
Helius Medical Technologies, Inc.
-- Studies uses Portable Neuromodulation Stimulator (PoNS®) to evaluate cranial-nerve non-invasive neuromodulation for gait/balance deficits in stroke patients -- -- Interaction with FDA on...
Helius Booth and Special Event at APTA Combined Sections Meeting Will Highlight Physical Therapists’ Ability to Customize PoNS Therapy® to Improve Gait in People with MS
February 05, 2024 07:05 ET
|
Helius Medical Technologies, Inc.
NEWTOWN, Pa., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) is expanding its presence at the 2024 American Physical Therapy Association (APTA) Combined Sections...
Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital
January 11, 2024 07:00 ET
|
Helius Medical Technologies, Inc.
-- Brooks Rehabilitation Hospital adds a second site to the registrational program in stroke, and brings the total number of patients to 100 -- -- Study uses Portable Neuromodulation Stimulator...
Helius Medical Technologies to Present at NobleCon19 Annual Conference
November 30, 2023 07:47 ET
|
Helius Medical Technologies, Inc.
NEWTOWN, Pa., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...